MedTrace Logo

ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers

NCT07238075 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 290

Last updated 2026-02-17

No results posted yet for this study

Summary

The purpose of this first-in-human study is to explore the safety, pharmacokinetics and effects of the study drug ADCX-020 in patients with advanced and metastatic solid tumors. ADCX-020 is an investigational anticancer therapy called antibody drug conjugate.

This study is set up in multiple parts. In the first part of the study, participants receive increasing doses of ADCX-020. Then 2 or more doses will be assessed to identify the optimal dose. This optimal dose is subsequently evaluated for effect on different cancer types.

Conditions

  • Advanced Malignancy
  • Advanced Solid Cancers
  • Metastatic Solid Tumors

Interventions

DRUG

ADCX-020

ADC

Sponsors & Collaborators

  • Adcytherix SAS

    lead INDUSTRY

Principal Investigators

  • Adcytherix · Adcytherix SAS

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-14
Primary Completion
2029-07-31
Completion
2029-11-30
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07238075 on ClinicalTrials.gov